We compared people who started GLP-1 drugs to people who did not, adjusting for differences in health history, demographics and other factors, and followed both groups for three years
The positive share price reaction reflected Wall Street's view that the once-daily tablet already FDA-approved earlier this year for obesity and overweight is on track to become a major player in type 2 diabetes treatment as well
This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License
Dealing With Nausea From Tirzepatide Nausea is one of the usual side effects tied to GLP-1 medications, Tirzepatide
Orlistat works in the gut to block fat absorption but may cause oily stools, gas, and urgency
How is investor sentiment shaping the obesity drug race